Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
NEW YORK - MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company focused on invariant natural killer T (iNKT) cell therapies with a market capitalization of $63 million, announced Monday the appointment of Colonel (Ret.) John B. Holcomb, MD, to its Board of Directors. The company’s stock has shown remarkable momentum, delivering a 100% return year-to-date according to InvestingPro data.
Dr. Holcomb, a trauma and critical care specialist, served 23 years in the U.S. Army, including roles as Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant to the Army Surgeon General. His career includes contributions to combat casualty care, transfusion medicine, and trauma systems design.
The appointment comes as MiNK continues developing its lead asset, AGENT-797, an allogeneic iNKT cell therapy currently in clinical trials for graft-versus-host disease, solid tumors, and pulmonary immune conditions.
"We are honored to welcome Dr. Holcomb to the MiNK Board at this transformative stage in our company’s journey," said Dr. Jennifer Buell, President and CEO of MiNK Therapeutics, in the company’s press release.
Dr. Holcomb has authored over 780 peer-reviewed publications and held leadership positions in prehospital blood transfusion programs. He joins the board alongside recently appointed pulmonary critical care expert Dr. Terese Hammond.
MiNK’s platform focuses on developing therapies that restore immune balance across cancer, immune-mediated diseases, and pulmonary immune failure. The company utilizes a cryopreserved manufacturing process for its cell therapies.
The information in this article is based on a press release statement from MiNK Therapeutics. The company’s next earnings report is scheduled for November 14, 2025.
In other recent news, MiNK Therapeutics has been in the spotlight following its second quarter 2025 financial results. The company reported a net loss of $4.2 million, translating to a loss of $1.06 per share. This financial performance was noted by H.C. Wainwright, which upgraded MiNK Therapeutics’ stock rating from Neutral to Buy, maintaining a price target of $35.00. The upgrade was attributed to the company’s financial results and recent capital-raising efforts. Additionally, MiNK Therapeutics reported an operating loss of $4.1 million for the quarter, which was higher than the previous quarter due to increased clinical program expenses. Despite these financial challenges, the company remains confident in its innovative programs and strategic partnerships. CEO Dr. Jennifer Buell highlighted MiNK’s advanced position in the iNKT cell therapy market. These developments indicate a strategic focus on growth and innovation amidst financial hurdles.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.